K. Venkatesan, J. Rual, A. Vazquez, U. Stelzl, I. Lemmens et al., An empirical framework for binary interactome mapping Estimating the size of the human interactome Predicting druggable binding sites at the protein-protein interface. Drug discovery today Transient protein-protein interactions: structural, functional, and network properties Diversity of protein-protein interactions, Nat Methods Proceedings of the National Academy of Sciences Structure The EMBO journal, vol.6, issue.22, pp.83-90, 1993.

S. Jones and J. Thornton, Principles of protein-protein interactions., Proceedings of the National Academy of Sciences, vol.93, issue.1, pp.13-20, 1996.
DOI : 10.1073/pnas.93.1.13

T. Clackson and J. Wells, A hot spot of binding energy in a hormone-receptor interface, Science, vol.267, issue.5196, pp.383-386, 1995.
DOI : 10.1126/science.7529940

B. Ma, R. Nussinov, /. Trp, and . Met, Phe hot spots in protein-protein interactions: potential targets in drug design. Current topics in medicinal chemistry, pp.999-1005, 2007.

B. Bullock, A. Jochim, and P. Arora, Assessing Helical Protein Interfaces for Inhibitor Design, Journal of the American Chemical Society, vol.133, issue.36, pp.14220-14223, 2011.
DOI : 10.1021/ja206074j

E. Lanzarotti, R. Biekofsky, E. Doa, M. Marti, and T. Ang, Aromatic???Aromatic Interactions in Proteins: Beyond the Dimer, Journal of Chemical Information and Modeling, vol.51, issue.7, pp.1623-1633, 2011.
DOI : 10.1021/ci200062e

F. Davis and A. Sali, The Overlap of Small Molecule and Protein Binding Sites within Families of Protein Structures, PLoS Computational Biology, vol.14, issue.2, p.1000668, 2010.
DOI : 10.1371/journal.pcbi.1000668.s009

D. Kozakov, D. Hall, G. Chuang, R. Cencic, R. Brenke et al., Structural conservation of druggable hot spots in protein-protein interfaces, Proceedings of the National Academy of Sciences, vol.108, issue.33, pp.13528-13561, 2011.
DOI : 10.1073/pnas.1101835108

T. Berg, Small-Molecule Inhibitors of Protein???Protein Interactions, Curr Opin Drug Discov Devel, vol.11, pp.666-74, 2008.
DOI : 10.1142/9781848163409_0012

D. Fry, Drug-Like Inhibitors of Protein-Protein Interactions: A Structural Examination of Effective Protein Mimicry, Current Protein & Peptide Science, vol.9, issue.3, pp.240-247, 2008.
DOI : 10.2174/138920308784533989

D. Fry, Protein???protein interactions as targets for small molecule drug discovery, Biopolymers, vol.47, issue.6, pp.535-552, 2006.
DOI : 10.1002/bip.20608

A. Wilson, Inhibition of protein???protein interactions using designed molecules, Chemical Society Reviews, vol.2, issue.12, pp.3289-3300, 2009.
DOI : 10.1039/b807197g

C. Wilson, M. Arkin, L. Vassilev, and D. Fry, Small-Molecule Inhibitors of IL-2/IL-2R: Lessons Learned and Applied, 2010.
DOI : 10.1007/82_2010_93

A. Higueruelo, A. Schreyer, G. Bickerton, W. Pitt, C. Groom et al., Atomic Interactions and Profile of Small Molecules Disrupting Protein-Protein Interfaces: the TIMBAL Database, Chemical Biology & Drug Design, vol.8, issue.5, pp.457-67, 2009.
DOI : 10.1111/j.1747-0285.2009.00889.x

R. Bourgeas, M. Basse, X. Morelli, and P. Roche, Atomic Analysis of Protein-Protein Interfaces with Known Inhibitors: The 2P2I Database, PLoS ONE, vol.5, issue.3, p.9598, 2010.
DOI : 10.1371/journal.pone.0009598.s006

A. Neugebauer, R. Hartmann, and C. Klein, Prediction of Protein???Protein Interaction Inhibitors by Chemoinformatics and Machine Learning Methods, Journal of Medicinal Chemistry, vol.50, issue.19, pp.4665-4668, 2007.
DOI : 10.1021/jm070533j

X. Morelli, R. Bourgeas, and P. Roche, Chemical and structural lessons from recent successes in protein???protein interaction inhibition (2P2I), Current Opinion in Chemical Biology, vol.15, issue.4, pp.475-81, 2011.
DOI : 10.1016/j.cbpa.2011.05.024

C. Reynes, H. Host, A. Camproux, G. Laconde, F. Leroux et al., Designing Focused Chemical Libraries Enriched in Protein-Protein Interaction Inhibitors using Machine-Learning Methods, PLoS Computational Biology, vol.7, issue.3, p.1000695, 2010.
DOI : 10.1371/journal.pcbi.1000695.s004
URL : https://hal.archives-ouvertes.fr/inserm-00705646

O. Sperandio, C. Reynes, A. Camproux, and B. Villoutreix, Rationalizing the chemical space of protein???protein interaction inhibitors, Drug Discovery Today, vol.15, issue.5-6, pp.220-229, 2010.
DOI : 10.1016/j.drudis.2009.11.007

K. Broos, M. Trekels, R. Jose, J. Demeulemeester, A. Vandenbulcke et al., Identification of a Small Molecule That Modulates Platelet Glycoprotein Ib-von Willebrand Factor Interaction, Journal of Biological Chemistry, vol.287, issue.12, pp.9461-72, 2012.
DOI : 10.1074/jbc.M111.311431

T. Liu, Y. Lin, X. Wen, R. Jorissen, and M. Gilson, BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities, Nucleic Acids Research, vol.35, issue.Database, pp.198-201, 2007.
DOI : 10.1093/nar/gkl999

P. Leeson and B. Springthorpe, The influence of drug-like concepts on decision-making in medicinal chemistry, Nature Reviews Drug Discovery, vol.2, issue.11, pp.881-90, 2007.
DOI : 10.1038/nrd2445

C. Lipinski, F. Lombardo, B. Dominy, and P. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced drug delivery reviews, pp.3-26, 2001.

D. Veber, S. Johnson, H. Cheng, B. Smith, K. Ward et al., Molecular Properties That Influence the Oral Bioavailability of Drug Candidates, Journal of Medicinal Chemistry, vol.45, issue.12, pp.2615-2638, 2002.
DOI : 10.1021/jm020017n

J. Hughes, J. Blagg, D. Price, S. Bailey, G. Decrescenzo et al., Physiochemical drug properties associated with in vivo toxicological outcomes, Bioorganic & Medicinal Chemistry Letters, vol.18, issue.17, pp.4872-4877, 2008.
DOI : 10.1016/j.bmcl.2008.07.071

T. Oltersdorf, S. Elmore, A. Shoemaker, R. Armstrong, D. Augeri et al., An inhibitor of Bcl-2 family proteins induces regression of solid tumours, Nature, vol.20, issue.7042, pp.677-81, 2005.
DOI : 10.1016/0014-5793(95)00062-E

S. Kortagere, M. Krasowski, and S. Ekins, The importance of discerning shape in molecular pharmacology, Trends in Pharmacological Sciences, vol.30, issue.3, pp.138-147, 2009.
DOI : 10.1016/j.tips.2008.12.001

I. Akritopoulou-zanze, J. Metz, and S. Djuric, Topography-biased compound library design: the shape of things to come? Drug discovery today, pp.948-952, 2007.

L. Akella and D. Decaprio, Cheminformatics approaches to analyze diversity in compound screening libraries, Current Opinion in Chemical Biology, vol.14, issue.3, pp.325-355, 2010.
DOI : 10.1016/j.cbpa.2010.03.017

G. Chessari and A. Woodhead, From fragment to clinical candidate???a historical perspective, Drug Discovery Today, vol.14, issue.13-14, pp.668-75, 2009.
DOI : 10.1016/j.drudis.2009.04.007

C. Reynolds, B. Tounge, and S. Bembenek, Ligand Binding Efficiency: Trends, Physical Basis, and Implications, Journal of Medicinal Chemistry, vol.51, issue.8, pp.2432-2440, 2008.
DOI : 10.1021/jm701255b

J. Baell and G. Holloway, New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays, Journal of Medicinal Chemistry, vol.53, issue.7, pp.2719-2759, 2010.
DOI : 10.1021/jm901137j

D. Lagorce, J. Maupetit, J. Baell, O. Sperandio, P. Tuffery et al., The FAF-Drugs2 server: a multistep engine to prepare electronic chemical compound collections, Bioinformatics, vol.27, issue.14, pp.2018-2038, 2011.
DOI : 10.1093/bioinformatics/btr333

S. Surade and T. Blundell, Structural Biology and Drug Discovery of Difficult Targets: The Limits of Ligandability, Chemistry & Biology, vol.19, issue.1, pp.42-50, 2012.
DOI : 10.1016/j.chembiol.2011.12.013